Cisplatin, a classical platinum-based chemotherapy agent, has been a frontline treatment for
various cancers for decades. However, its effectiveness has been hindered by the …

Decitabine's early successful therapeutic outcomes in hematologic malignancies have led to
regulatory approvals from the Food and Drug Administration (FDA) and the European …

In contrast to other types of cancers, there is no available efficient pharmacological treatment
to improve the outcomes of patients suffering from major primary liver cancers, ie …

The protein family of poly (ADP-ribose) polymerases (PARPs) is comprised of multifunctional
nuclear enzymes. Several PARP inhibitors have been developed as new anticancer drugs …

Simple Summary Resistance to chemotherapy in patients with high-grade serous ovarian
carcinoma is a clinically relevant problem, and it results in high mortality. The aim of the …

Background Gastric cancer (GC) is a significant cancer-related cause of death worldwide.
GC's most used chemotherapeutic regimen is based on platinum drugs such as cisplatin …

N6-methyladenosine (m6A) RNA methylation, a dynamic regulator of transcript expression,
plays a pivotal role in cancer by influencing diverse mRNA processes, including nuclear …

In this last decade, our understanding of the complex factors and processes that drive
cancer development and progression has broadened in scope and grown in depth. Today, it …

RNA modifications, collectively known as epitranscriptomic modifications, have emerged as
critical regulators of gene expression, cellular adaptation, and therapeutic resistance. This …